6 Top Gainers In Healthcare Sector (NMRD, PTI, MGTA...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Nemaura Medical Inc. (NMRD)

Gained 22.33% to close Monday's (Feb.11) trading at $1.26.

Nemaura is a medical technology company developing sugarBEAT, a non-invasive Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics.

News: The Company announced that Dr. Fred Schaebsdau has joined Nemaura to lead strategy and business development.

Schaebsdau will advance Nemaura's commercial strategy for its planned launch of SugarBEAT in Europe, and advise regarding its upcoming 510(k) submission to the FDA. He will also be named to Nemaura's Scientific Advisory Board.

Near-term Catalysts:

-- Submission of sugarBEAT De-Novo 510(k) application to the FDA during Q1 2019. -- SugarBEAT is currently undergoing CE review in the EU, with the final stages of the review and clinician sign off now expected to be completed in early 2019, after which Nemaura expects CE approval will be issued.

2. Proteostasis Therapeutics Inc. (PTI)

Proteostasis Therapeutics Is a clinical-stage biopharmaceutical company with a main focus on developing therapies to treat cystic fibrosis.

Gained 21.81% to close Monday's trading at $3.91.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase I study of the Company's proprietary combination therapy triplet (PTI-808, PTI-801, and PTI-428) in cystic fibrosis is ongoing, with data expected in the first quarter of 2019. -- Studies exploring a proprietary doublet (PTI-808 and PTI-801), and separate studies of PTI-801 and PTI-428 with background SYMDEKO therapy, in cystic fibrosis subjects, are underway, with data expected from all the studies in the first quarter of 2019.

3. Replimune Group Inc. (REPL)

Replimune is a biotechnology company developing oncolytic immunotherapies for the treatment of cancer.

Gained 19.06% to close Monday's trading at $16.24.

News: No news

Clinical Trials & Near-term Catalysts:

The lead product candidate is RP1 for advanced solid tumors.

RP1 is in a two-part Phase 1/2 clinical trial in collaboration with Bristol Myers Squibb.

In part one of the Phase 1/2 clinical trial, the Company is testing RP1 administered alone in patients with advanced solid tumors followed by dosing in combination with blockbuster drug Opdivo. In part two of the Phase 1/2 clinical trial, Replimune intends to study the safety and efficacy of RP1 in combination with Opdivo in four cohorts of patients with different solid tumor types.

-- Data from the full Phase 1 part of the Phase 1/2 study of RP1 alone and RP1 combined with Opdivo is expected to be presented at a medical conference in the second half of 2019. -- Initiate the Phase 2 portion of the study in the first half of 2019 in four cohorts of approximately 30 patients each with melanoma, bladder cancer, microsatellite instability-high cancers, and non-melanoma skin cancers. -- Initiate the registration-directed randomized, controlled Phase 2 clinical trial of RP1 in combination with approved drug Libtayo in cutaneous squamous cell carcinoma in the first half of 2019. Libtayo is jointly developed by Regeneron and Sanofi.

Next up in the pipeline is RP2 for mixed advanced solid tumors, including triple negative breast cancer, and RP3, an oncolytic immuno-gene therapy.

-- Initiate the clinical development of RP2 in Phase 1 clinical trial of RP2 alone and in combination with anti-PD1 therapy in the first half of 2019. -- Initiate the clinical development of RP3 in Phase 1 clinical trial of RP3 alone and in combination with anti-PD1 therapy in the first half of 2020.

4. Enochian Biosciences Inc. (ENOB)

Enochian Biosciences is a gene-modified cell therapy company developing potentially curative and preventative therapies for HIV and cancer.

Gained 18.38% to close Monday's trading at $8.50.

News: No news

Recent event:

The Company's shares were uplisted to the NASDAQ Capital Market from the Over-the-Counter Bulletin Board on December 10, 2018.

5. Entera Bio Ltd. (ENTX)

Entera Bio is a clinical-stage biopharmaceutical company focused on developing orally-delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs.

Gained 15.20% to close Monday's trading at $4.85.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase II clinical trial of Oral PTH 1-34 for hypoparathyroidism is underway. The Company reported positive results from Part I of this study last November. -- A phase II study of oral parathyroid hormone drug, EB612, in hypoparathyroidism patients is underway.

6. Magenta Therapeutics (MGTA)

Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients.

Gained 13.89% to close Monday's trading at $8.53.

News: No news

Clinical Trials & Near-term Catalysts:

The most advanced product candidate is MGTA-456, under a phase II trial in inherited metabolic disorders, and a phase II study in blood cancers.

Next up in the pipeline is MGTA-145, a novel stem cell mobilization product candidate intended to achieve mobilization of high numbers of stem cells in a single day to replace granulocyte colony-stimulating factor, or G-CSF, the current standard of care. MGTA-145 is expected to enter into clinical testing in the first half of 2019.